Lumibird SA Asset Resilience Ratio
Lumibird SA asset resilience ratio. Lumibird SA (LBIRD) has an Asset Resilience Ratio of 22.85% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LBIRD cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Lumibird SA (2000–2024)
Asset resilience ratio of Lumibird SA from 2000 to 2024. This chart shows how Lumibird SA's Asset Resilience Ratio has changed over time. Read total liabilities of Lumibird SA for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Lumibird SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Lumibird SA assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €45.19 Million | 10.37% |
| Short-term Investments | €54.43 Million | 12.49% |
| Total Liquid Assets | €99.62 Million | 22.85% |
Asset Resilience Insights
- Good Liquidity Position: Lumibird SA maintains a healthy 22.85% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Lumibird SA Industry Peers by Asset Resilience Ratio
Compare Lumibird SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.16% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193 |
Diagnostics & Research | 70.50% |
|
Krsnaa Diagnostics Limited
NSE:KRSNAA |
Diagnostics & Research | 9.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
Lumibird SA Asset Resilience Ratio by Year (2000–2024)
Lumibird SA asset resilience ratio by year from 2000 to 2024. The table below shows the annual Asset Resilience Ratio data for Lumibird SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 12.73% | €54.71 Million ≈ $63.97 Million |
€429.80 Million ≈ $502.48 Million |
+4.81pp |
| 2023-12-31 | 7.92% | €32.08 Million ≈ $37.51 Million |
€405.25 Million ≈ $473.78 Million |
+1.13pp |
| 2022-12-31 | 6.79% | €25.26 Million ≈ $29.53 Million |
€372.04 Million ≈ $434.96 Million |
+6.07pp |
| 2021-12-31 | 0.72% | €2.50 Million ≈ $2.93 Million |
€347.62 Million ≈ $406.41 Million |
+38.87pp |
| 2020-12-31 | -38.15% | €-116.51 Million ≈ $-136.22 Million |
€305.43 Million ≈ $357.08 Million |
-38.16pp |
| 2019-12-31 | 0.02% | €30.00K ≈ $35.07K |
€193.76 Million ≈ $226.52 Million |
-0.02pp |
| 2018-12-31 | 0.04% | €53.00K ≈ $61.96K |
€151.03 Million ≈ $176.58 Million |
-14.26pp |
| 2017-12-31 | 14.30% | €17.31 Million ≈ $20.24 Million |
€121.08 Million ≈ $141.55 Million |
+10.51pp |
| 2016-12-31 | 3.79% | €2.32 Million ≈ $2.71 Million |
€61.19 Million ≈ $71.54 Million |
+13.41pp |
| 2015-12-31 | -9.63% | €-5.88 Million ≈ $-6.88 Million |
€61.11 Million ≈ $71.44 Million |
-11.23pp |
| 2013-12-31 | 1.60% | €825.00K ≈ $964.51K |
€51.49 Million ≈ $60.20 Million |
+0.06pp |
| 2012-12-31 | 1.54% | €814.00K ≈ $951.65K |
€52.71 Million ≈ $61.62 Million |
+0.45pp |
| 2011-12-31 | 1.09% | €637.00K ≈ $744.72K |
€58.29 Million ≈ $68.15 Million |
+0.09pp |
| 2010-12-31 | 1.01% | €557.00K ≈ $651.19K |
€55.28 Million ≈ $64.63 Million |
+0.16pp |
| 2009-12-31 | 0.85% | €463.00K ≈ $541.30K |
€54.77 Million ≈ $64.03 Million |
+0.02pp |
| 2007-12-31 | 0.82% | €572.00K ≈ $668.73K |
€69.41 Million ≈ $81.14 Million |
+0.15pp |
| 2006-12-31 | 0.67% | €372.00K ≈ $434.91K |
€55.22 Million ≈ $64.56 Million |
-0.04pp |
| 2005-12-31 | 0.72% | €314.00K ≈ $367.10K |
€43.91 Million ≈ $51.34 Million |
+0.17pp |
| 2004-12-31 | 0.54% | €147.00K ≈ $171.86K |
€27.20 Million ≈ $31.80 Million |
-0.59pp |
| 2003-12-31 | 1.13% | €317.00K ≈ $370.61K |
€28.16 Million ≈ $32.92 Million |
+0.91pp |
| 2002-12-31 | 0.22% | €69.00K ≈ $80.67K |
€31.96 Million ≈ $37.37 Million |
+0.12pp |
| 2001-12-31 | 0.09% | €31.00K ≈ $36.24K |
€33.26 Million ≈ $38.88 Million |
-0.02pp |
| 2000-12-31 | 0.12% | €206.00K ≈ $240.84K |
€175.71 Million ≈ $205.42 Million |
-- |
About Lumibird SA
Lumibird SA designs, manufactures, and sells various lasers for scientific, industrial, and medical applications in France, Hong Kong, the United States, Germany, South Korea, China, and Austria. The company operates through Photonics and Medical divisions. It offers fiber lasers and amplifiers, high power fiber lasers, and solid-state lasers, laser diodes and components; and doppler wind LiDAR, … Read more